Pharmaceutical Business Investment Opportunities

• Poland-based pharmaceutical manufacturing company developing a state-of-the-art production facility for pharmaceutical-grade cannabis flos in Częstochowa. • The facility will manufacture medical cannabis raw material for pharmaceutical applications with an estimated initial production capacity of approximately 2,000 kg per month. • Partial commercial operations are expected to commence in the first quarter of next year, with full-scale operations planned for the second quarter. • A Letter of Intent (LOI) has been signed with a pharmaceutical company for the purchase of the raw material, providing an established sales pipeline upon commencement of production. • The business will operate through three revenue streams: production of pharmaceutical-grade medical cannabis in cooperation with a state scientific institute under GMP standards; import of GACP-certified raw material for value-added GMP processing under the company's own certification, with processing capacity of up to 2,000 kg per month; and B2B contract packaging and laboratory testing services for third parties. • The facility will include an advanced physicochemical laboratory equipped with technologies such as HPLC and ICP-MS to support quality control, research, and commercial testing services. • The business is being developed with a scalable manufacturing model designed to serve pharmaceutical companies and other licensed industry participants. • Well positioned to capitalize on the growing demand for pharmaceutical-grade medical cannabis and contract manufacturing services in regulated European markets.

Pharmaceutical marketing company headquartered in Pune, with distribution coverage across India. - Product portfolio includes over 25 formulations and 75+ SKUs. - All formulations/SKUs are manufactured through certified third-party partners, all holding valid FSSAI and FDA registrations. - Partnered with over 8,000 doctors across the country, enabling regular prescriptions and sustained product demand, supplied through distributors. - The company is currently focused primarily on five states in South and West India and is planning expansion into North India. - Operates as a pure marketing and distribution model with no in-house manufacturing, keeping overheads low. - The business operated as a partnership firm and was incorporated as a Private Limited company three years ago. - GST certified and fully compliant with applicable pharmaceutical marketing norms and regulations.

Pharmaceutical marketing company headquartered in Pune, with distribution coverage across India. - Product portfolio includes over 25 formulations and 75+ SKUs. - All formulations/SKUs are manufactured through certified third-party partners, all holding valid FSSAI and FDA registrations. - Partnered with over 8,000 doctors across the country, enabling regular prescriptions and sustained product demand, supplied through distributors. - The company is currently focused primarily on five states in South and West India and is planning expansion into North India. - Operates as a pure marketing and distribution model with no in-house manufacturing, keeping overheads low. - The business operated as a partnership firm and was incorporated as a Private Limited company three years ago. - GST certified and fully compliant with applicable pharmaceutical marketing norms and regulations.

Private pharmaceutical manufacturing company with over three decades of operating history and WHO-GMP certified manufacturing facilities. - Manufactures pharmaceutical injections, eye drops, and ointments for regulated and semi-regulated markets across 20 countries. - Has secured more than 250 product approvals, demonstrating strong regulatory capabilities and a diversified product portfolio. - The business has an incorporation certificate and GST certificate. - The company operates a highly automated pharmaceutical manufacturing facility, enabling high production volumes and revenue generation with a relatively lean workforce. - Not a USFDA approved company.

Promoter experience: - The CEO brings 12+ years of pharmaceutical commercialisation and GTM strategy across EU and GCC markets, with experience leading €40M+ product launches through Temple Group. The scientific and clinical advisory team draws on backgrounds from Pfizer, TCD, RCSI, the Pasteur Institute, and NCRI. Scientific foundation: - The platform is built on 3,400+ peer-reviewed studies on core bioactive compounds — azadirachtin, gedunin, nimbin, and nimbolide — published between the last 25 years. - Efficacy is scientifically established; the patent landscape remains open. Revenue model: - Three streams in sequence: Direct-to-consumer and pharmacy sales (from Year 1), prescription therapeutics and clinical licensing (from Year 2), and molecule licensing and pharma co-development agreements (from Year 3). 15% of net profit is ring-fenced annually into R&D. IP & regulatory positioning: - Patent filings on novel botanical molecule derivatives are planned within 18 months of production launch. Ireland's Knowledge Development Box provides a 6.25% effective tax rate on qualifying patent income which is a structural advantage for an IP-led business. Incorporation: - We are an registered Irish company, incorporated in Dublin, with full corporate documentation in place. Stage: - Pre-revenue, pre-clinical, with the lead product (psoriasis cream) entering production this year.

* Established wellness, cosmetic, herbal, and e-commerce-focused business ecosystem operating for the past 12 years. * Achieved approximately INR 7.5 crore annual turnover through multi-platform e-commerce sales across Amazon, Flipkart, Meesho, and other digital marketplaces. * Previously generated peak combined daily sales of approximately INR 2.5 lakh to INR 3 lakh across major online platforms. * Built and managed 1,000+ online product listings across cosmetic, wellness, herbal, personal care, ampoule, capsule, and lifestyle product categories. * Operates a high-margin direct-to-consumer business model supported by low manufacturing costs, premium marketplace positioning, and scalable digital marketing strategies. * Established customer reach across India with thousands of completed e-commerce orders and repeat customer engagement through marketplace and social media channels. * Promoters possess over 10 years of practical experience in e-commerce operations, cosmetic product development, marketplace scaling, digital branding, product packaging, consumer psychology, and viral marketing strategies. * Strong operational expertise across Amazon, Flipkart, Meesho, YouTube marketing, D2C branding, product positioning, and e-commerce conversion optimization. * Existing business relationships with raw material suppliers, packaging vendors, logistics partners, e-commerce ecosystems, and manufacturing-related networks. * Currently transitioning into a professionally structured private limited company, with expansion plans focused on premium packaging, wellness café systems, herbal tea ecosystems, franchise models, AI-driven wellness branding, and global e-commerce growth.

Proposed pharma marketing company focused on general medicine, pain relief, dermatology, and skincare products. - Business plans to operate through a third-party manufacturing model, reducing upfront manufacturing infrastructure costs. - Intends to build and market its own branded pharmaceutical and skincare product portfolio. - Targeting prescription-based and OTC segments with products similar to common general medicine and skincare categories. - Founder is seeking strategic investment to launch operations, build distribution, and scale brand presence in the market. - Business is currently at the pre-operational stage with initial planning and product positioning already identified. - Lean operating structure with low fixed asset requirements due to outsourced manufacturing setup. - Based in Karnal, Haryana, with plans to expand through pharma distributors, medical representatives, and retail pharmacy networks. - The business is currently unregistered and the registration process is underway.

The business operates as a franchised distributor of a generic pharmaceutical manufacturer. - It purchases stock directly from the manufacturer without paying royalties. - The franchise agreement has no fixed tenure and can be renewed easily. - The business serves 25 B2B clients. - It operates as a sole proprietorship with a valid drug license and MSME registration.

Developing a novel pharmaceutical drug targeting the treatment of chronic and episodic migraine conditions. - Designed to address neurological conditions, including trigeminal neuralgia, through specialized therapeutic intervention. - Intended for use in clinical settings under supervision of medical professionals. - Currently in pre-revenue stage with no commercial sales, as the product is awaiting clinical trial progression. - Registered under the FDA IND pathway, indicating initial regulatory alignment for clinical development. - Further regulatory approvals, such as successful completion of clinical trials and drug approval, will be required before commercialization. - Positioned as an early-stage drug development opportunity within the neurology and pain management segment. - Focused on addressing unmet medical needs in migraine and related neurological disorders.

Pharmaceutical marketing company focused on branded formulations, expanding presence in Delhi and northern India. - Markets a portfolio of products, including Cefixi O tab, Levista AM tab, Vista SP tab, FPM tab, Esom LS Cap, and Vista UP syrup. - Products cater to various therapeutic segments and are prescribed by doctors and healthcare providers. - Operates on an outsourced manufacturing model while selling under its own brand. - Serves 50–60 doctors and clinics, indicating an established prescriber network. - Generates revenue through product sales via medical representatives and direct distribution to clinics. - Led by a promoter with around 20 years of experience in the pharmaceutical industry. - Holds valid drug license, ensuring regulatory compliance. - Built a foundation for expansion with growing doctor network and regional market focus.

• Manufacturer and exporter of homeopathic OTC products, offering a wide portfolio including single remedy pills, dilutions, tablets, pellets, family kits, and blank sugar globules. • Operates as a digitally native, direct-to-consumer (D2C) brand with sales infrastructure built for its own website and major US marketplaces such as Amazon, eBay, and Walmart. • Holds a rare multinational structure with legal entities in the United States, India, and Canada, enabling global operations and regulatory alignment. • Manufacturing facility in India is US FDA registered and has undergone multiple inspections, with only minor observations in the latest review and clearance expected to resume exports. • Owns a US FDA Drug Master File (Type IV) for homeopathic blank pellets, positioning the business as a qualified global supplier of pharmaceutical-grade excipients. • Portfolio includes thousands of OTC SKUs listed with the US FDA, reflecting significant product depth and regulatory groundwork. • Brand is a registered trademark in the United States, strengthening intellectual property protection and market positioning. • Demonstrates strong customer validation through high ratings across major marketplaces and its own platform, indicating product acceptance despite pre-revenue status. • US-based fulfillment center is FDA-inspected with no observations, capable of handling large-scale order volumes and compliant with cGMP standards including recalls and complaint handling. • Backed by a founding team with decades of domain experience in homeopathy and established industry presence. • Built a scalable proprietary e-commerce infrastructure integrated with production systems and third-party platforms, ready to support high SKU and order volumes. • Currently pre-revenue with no sales recorded yet from the India facility; regulatory processes including US FDA inspection are in progress.

Operates a pharmaceutical marketing business focused on selling registered trademark products across India. - Markets products across general medicine, diabetic care, and proton pump inhibitor (PPI) segments. - Supplies to healthcare channels and end customers through an established distribution approach. - Maintains ready stock to support ongoing demand and timely order fulfillment. - Handles approximately 5–6 consignments per week, indicating active operations. - Fully compliant with required regulations, holding valid drug and food licenses.